ASH Clinical News May 2017 NEW | Page 39

CLINICAL NEWS
“acceptable” rate of GVHD (30%; 95% CI
9.9-50.1).
Dr. Herbaux and colleagues collected
patient data from the French Medical Drug
Agency’s Authorization for Temporary Use
program to identify participants who had
undergone alloHCT between March and
September 2015. Most patients were male
(n=11; 55%) and had an Eastern Coopera-
tive Oncology Group performance status
score of ≤1 (n=15; 75%).
Patients had received a median of seven
prior therapies (range = 4-13 therapies).
Most (n=13; 65%) had a history of GVHD:
10 had acute GVHD and three had chronic
GVHD. Two patients had an improved
response 100 days post-transplant, convert-
ing from partial response (PR) to complete
response (CR).
Six patients (95% CI 9.9-50.1) experi-
enced nivolumab-induced GVHD after a
single infusion, which prompted discon-
tinuation of the drug. Each of these cases
occurred at least one week after infusion,
and all patients who experienced GVHD
had a history of acute GVHD, “which
might reflect greater alloreactivity,” co-
author Franck Morschhauser, MD, PhD,
told ASH Clinical News. “Intriguingly,
nivolumab did not induce chronic GVHD
in any patients,” he noted.
Other reasons for treatment discontinu-
ation included second alloHCT (n=1), lack
T:7”
REVLIMID ® [lenalidomide] capsules, for oral use
Allergic Reactions
Inform patients of the potential for allergic reactions including
hypersensitivity, angioedema, Stevens-Johnson Syndrome, or toxic
epidermal necrolysis if they had such a reaction to THALOMID and report
symptoms associated with these events to their healthcare provider for
evaluation [see Warnings and Precautions (5.8)].
Tumor Lysis Syndrome
Inform patients of the potential risk of tumor lysis syndrome and to
report any signs and symptoms associated with this event to their
healthcare provider for evaluation [see Warnings and Precautions (5.9)].
Tumor Flare Reaction
Inform patients of the potential risk of tumor flare reaction and to report
any signs and symptoms associated with this event to their healthcare
provider for evaluation [see Warnings and Precautions (5.10)].
Dosing Instructions
Inform patients how to take REVLIMID [see Dosage and Administration
(2)]
• REVLIMID should be taken once daily at about the same time each
day,
• REVLIMID may be taken either with or without food.
• The capsules should not be opened, broken, or chewed. REVLIMID
should be swallowed whole with water.
• Instruct patients that if they miss a dose of REVLIMID, they may still
take it up to 12 hours after the time they would normally take it. If
more than 12 hours have elapsed, they should be instructed to skip
the dose for that day. The next day, they should take REVLIMID at
the usual time. Warn patients to not take 2 doses to make up for the
one that they missed.
Manufactured for:
Celgene Corporation
Summit, NJ 07901
REVLIMID ® , REVLIMID REMS ® and THALOMID ® are registered trademarks
of Celgene Corporation.
Pat. www.celgene.com/therapies
©2005-2017 Celgene Corporation, All Rights Reserved.
REV_MM_MAINT_HCP_BSv.21 2_2017
REVLIMID REMS program
Because of the risk of embryo-fetal toxicity, REVLIMID is only ava